Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • rainbow over text: 'thank you NHS'
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Glycomimetics Inc (GLYC) USD0.001

Sell:$2.95 Buy:$2.96 Change: $0.08 (2.79%)
Market closed |  Prices as at close on 5 June 2020 | Switch to live prices |
Change: $0.08 (2.79%)
Market closed |  Prices as at close on 5 June 2020 | Switch to live prices |
Change: $0.08 (2.79%)
Market closed |  Prices as at close on 5 June 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. Its drug candidates include Uproleselan, GMI-1687, GMI-1359, Galectin Antagonists and Rivipansel. Uproleselan is a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia and a hematologic cancer. As a life-cycle extension to uproleselan, it has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is designed to inhibit both E-selectin and CXCR4. The Galectin-3 is a carbohydrate-binding protein. Rivipansel is a glycomimetic drug that acts as a pan-selectin antagonist that binds to all three members of the selectin family, E-, P- and L-selectin, for the treatment of vaso-occlusive crisis.

Contact details

9708 Medical Center Dr
United States
+1 (240) 2431201

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$123.34 million
Shares in issue:
43.58 million
United States
US dollar

Key personnel

  • Timothy Pearson
    Independent Chairman of the Board
  • Rachel King
    President, Chief Executive Officer, Co-Founder, Director
  • John Magnani
    Co-Founder, Senior Vice President, Chief Scientific Officer
  • Brian Hahn
    Chief Financial Officer
  • Armand Girard
    Senior Vice President, Chief Business Officer
  • Helen Thackray
    Senior Vice President - Clinical Development, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.